Sort   by:  
 Page size 
UnknownPrevalence and Correlates of Youth Suicidal Ideation and Attempts: Evidence from the 2014 Ontario Child Health Study.

Objectives

To present the 12-month prevalence and correlates of suicidal ideation and attempts in a sample of youth in Ontario.

Methods

Data come from the 2014 Ontario Child Health Study, a provincially representative survey of families with children in Ontario. Youth aged 14 to 17 y ...
S-EPMC6463356 | biostudies-literature
UnknownChanges in the Prevalence of Child and Youth Mental Disorders and Perceived Need for Professional Help between 1983 and 2014: Evidence from the Ontario Child Health Study.

Objectives

To examine: 1) changes in the prevalence of mental disorders and perceived need for professional help among children (ages 4 to 11) and youth (ages 12 to 16) between 1983 and 2014 in Ontario and 2) whether these changes vary by age and sex, urban-rural residency, poverty, lone-par...
S-EPMC6463358 | biostudies-literature
UnknownSix-Month Prevalence of Mental Disorders and Service Contacts among Children and Youth in Ontario: Evidence from the 2014 Ontario Child Health Study.

Objectives

To present the 6-month prevalence and sociodemographic correlates of mental disorders and mental health-related service contacts in a sample of children (4 to 11 years) and youth (12 to 17 years) in Ontario.

Methods

The 2014 Ontario Child Health Study is a provincially repr...
S-EPMC6463361 | biostudies-literature
UnknownThe 2014 Ontario Child Health Study-Methodology.

Objective

To describe the methodology of the 2014 Ontario Child Health Study (OCHS): a province-wide, cross-sectional, epidemiologic study of child health and mental disorder among 4- to 17-year-olds living in household dwellings.

Method

Implemented by Statistics Canada, the 2014 OCHS...
S-EPMC6463362 | biostudies-literature
UnknownTracking Children's Mental Health in the 21st Century: Lessons from the 2014 OCHS.
Not available
S-EPMC6463360 | biostudies-literature
ProteomicsOstreococcus OlV1/OlV7 lysate DOM
Dissolved organic matter extracts prepared by viral lysates of Ostreococcus lucimarinus CCMP2972, infected by lytic viruses OlV1 and OlV7, as well as uninfected controls, under standard-light (~110uE/m2s; "SL") and low-light (15uE/m2s, "LL") irradiance.
ORGANISM(S): Ostreococcus Lucimarinus Cce9901 (ncbitaxon:436017) Ostreoccus Lucimarinus Virus Olv7 Ostreococcus Lucimarinus Virus 1 (ncbitaxon:880162) 
2019-02-12 | MSV000083434 | MassIVE
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
The ODYSSEY OUTCOMES trial, comprising over 47 000 patient-years of placebo-controlled observation, demonstrated important reductions in the risk of recurrent ischaemic cardiovascular events with the monoclonal antibody to proprotein convertase subtilisin/kexin type 9 alirocumab, as well as lower al...
S-EPMC11249957 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.

Background

Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patie...
S-EPMC8822604 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Background

Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain.

Met...

S-EPMC9422774 | biostudies-literature
Sort   by:  
 Page size